Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours

A J Zurita1, M Khajavi1, H-K Wu1, L Tye2, X Huang2, M H Kulke3, H-J Lenz4, N J Meropol5, W Carley2,6, S E DePrimo2,6, E Lin1, X Wang1, C S Harmon*2,7,8 and J V Heymach*1,7

1University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1374 Houston, TX, USA; 2Pfizer Inc., La Jolla, CA, USA; 3Dana-Farber Cancer Institute, Boston, MA, USA; 4USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA and 5University Hospitals Case Medical Center Seidman Cancer Center, Case Comprehensive Cancer Center and Case Western Reserve University, Cleveland, OH, USA

**Background:** Sunitinib is approved worldwide for treatment of advanced pancreatic neuroendocrine tumours (pNET), but no validated markers exist to predict response. This analysis explored biomarkers associated with sunitinib activity and clinical benefit in patients with pNET and carcinoid tumours in a phase II study.

**Methods:** Plasma was assessed for vascular endothelial growth factor (VEGF)-A, soluble VEGF receptor (sVEGFR)-2, sVEGFR-3, interleukin (IL)-8 (n = 105), and stromal cell-derived factor (SDF)-1α (n = 28). Pre-treatment levels were compared between tumour types and correlated with response, progression-free (PFS), and overall survival (OS). Changes in circulating myelomonocytic and endothelial cells were also analysed.

**Results:** Stromal cell-derived factor-1α and sVEGFR-2 levels were higher in pNET than in carcinoid (P = 0.003 and 0.041, respectively). High (above-median) baseline SDF-1α was associated with worse PFS, OS, and response in pNET, and high sVEGFR-2 with longer OS (P ≤ 0.05). For carcinoid, high IL-8, sVEGFR-3, and SDF-1α were associated with shorter PFS and OS, and high IL-8 and SDF-1α with worse response (P ≤ 0.05). Among circulating cell types, monocytes showed the largest on-treatment decrease, particularly CD14+ monocytes co-expressing VEGFR-1 or CXCR4.

**Conclusions:** Interleukin-8, sVEGFR-3, and SDF-1α were identified as predictors of sunitinib clinical outcome. Putative pro-tumorigenic CXCR4+ and VEGFR-1+ monocytes represent novel candidate markers and biologically relevant targets explaining the activity of sunitinib.
Sunitinib biomarkers in advanced NETs

differentiation, proliferation rate, site of origin, and the presence, site, and extent of metastases (Panzuto et al, 2005, 2011; Pape et al, 2008; Bosman, 2010). Although surgery is potentially curative in patients with early disease, patients with advanced stages have limited therapeutic options (Auernhammer and Goke, 2011; Kulke et al, 2011).

Agents targeting the vascular endothelial growth factor (VEGF) signalling pathway are in clinical testing for patients with advanced NETs. These tumours, particularly pNET, are highly vascularized and express VEGF-A (henceforth referred to as VEGF) and its receptors VEGFR-2 and VEGFR-3 (Hansel et al, 2003), suggesting that VEGF activation may promote NET growth. In addition, implicated in NET pathogenesis are the platelet-derived growth factors (PDGFs; Fjallskog et al, 2003) and stem cell factor (SCF) (Zhang et al, 2009). VEGF-targeted agents appear to be more effective in pNET than in carcinoid, much similar to chemotherapy. Results from a randomized phase III trial (Raymond et al, 2011) led to the international approval of the multitargeted tyrosine kinase inhibitor sunitinib (SUTENT, Pfizer Inc., New York, NY, USA), which inhibits VEGFR-1, -2, and -3, PDGFR-α and -β, and SCF receptor (KIT), for unreactable, locally advanced or metastatic pNET.

Owing to the heterogeneity in clinical behaviour and treatment response of NETs, to optimize treatment doses and combinations and to discern mechanisms underlying resistance, biomarkers are critically needed. No marker however has yet been fully validated for any of these purposes, but circulating candidates for sunitinib have been identified in different tumour types (Gerger et al, 2011). Our goal was therefore to identify blood markers associated with prognosis and/or sunitinib efficacy and biological activity in patients with advanced pNET and carcinoid tumours, using specimens from a phase II study (Kulke et al, 2008). We decided to include VEGF, soluble (s)VEGFR-2, sVEGFR-3, interleukin (IL)-8, stromal cell-derived factor (SDF)-1, and circulating endothelial cells (CECs) in this analysis because of their implication in angiogenesis and sunitinib’s activity, together with the results of prior correlative studies, suggesting prognostic value for circulating VEGF and IL-8 in NETs (Pavel et al, 2005; Deprimo et al, 2007; Norden-Zloni et al, 2007; Abdel-Rahman, 2014). As specific types of myeloid cells are pro-tumorigenic and may mediate anti-VEGF treatment resistance, we decided to include them as well (Norden-Zloni et al, 2007; Bergers and Hanahan, 2008; Du et al, 2008).

MATERIALS AND METHODS

Patients and treatment. The design and main results of the phase II study (NCT00056693) are reported elsewhere (Kulke et al, 2008). Briefly, patients with histologic evidence of pNET or carcinoid tumours, who were not candidates for curative surgery were treated with repeated self-administered 6-week cycles of oral sunitinib (50 mg per day for 4 weeks, followed by 2 weeks off treatment). Patients were observed for response, survival, and adverse events, and treatment was continued until disease progression, unacceptability, or withdrawal of consent.

Sample collection and analytical methods. All patients provided written Institutional Review Board-approved informed consent to collect blood samples for biomarker analysis. Specimens for soluble protein assessment were collected on days 1, 14 (C1D14), and 28 (C1D28) of cycle 1, and days 1 and 28 of cycles 2 – 4 (C2D1 refers to cycle 2 day 1; online only). Vascular endothelial growth factor, IL-8, sVEGFR-2, and sVEGFR-3 concentrations were measured by enzyme-linked immunosorbent assay (ELISA). Stromal cell-derived factor-1α, a small cytokine modulated by sunitinib (Ebos et al, 2007), was measured in a subset of 28 patients with corresponding peripheral blood mononuclear cell fraction specimens available (Supplementary Table S1). Validated ELISA kits or kit components (R&D Systems, Minneapolis, MN, USA) were used to measure the proteins in heparin plasma.

EDTA plasma samples for combined trough levels of sunitinib and its active metabolite SU12662 were obtained before dosing on days 1, 14, and 28 of cycles 1, 2, and 3, respectively. All assays were run under Good Laboratory Practice conditions, using previously described liquid chromatography/mass spectrometry methodology (Deprimo et al, 2007).

White blood cell (WBC) counts were obtained from automated differentials. Circulating endothelial cells and myelomonocytic cell subsets were quantified by eight-colour flow cytometry using a FACSCanto analyser (BD Biosciences, San Jose, CA, USA). Peripheral blood mononuclear cells were isolated and stained as previously described, with modifications (Supplementary Methods, Supplementary Figure S1, and Supplementary Table S2; Bergers and Hanahan, 2008; Mancuso et al, 2009). To minimize inter-assay variability, baseline and subsequent follow-up specimens from individual patients were thawed and analysed in a single batch.

Statistical analyses. Wilcoxon signed-rank and rank-sum tests were used to compare changes in soluble protein levels and cell populations. Clinical benefit response (CBR) was defined as a complete or partial response (by Response Evaluation Criteria in Solid Tumors (RECIST)) or stable disease for > 6 months. The Spearman correlation coefficient was used to assess the relationship between changes in cellular and plasma markers, and tumour burden. Log-rank test was used to analyse progression-free survival (PFS) and overall survival (OS). Cox proportional hazards models were fitted to assess the association between clinical outcomes and protein biomarkers. Owing to the exploratory nature of these studies, screening candidate angiogenic markers for usefulness as biomarkers in advanced NETs, no correction for multiple testing was performed. All statistical analyses were completed using SAS 9.1 for Windows (SAS Institute Inc., Cary, NC, USA).

RESULTS

Baseline VEGF, sVEGFR-2, sVEGFR-3, IL-8, and SDF-1α. Of the 107 patients receiving sunitinib, 105 (66 pNET and 39 carcinoi) had data evaluable for soluble biomarkers, with the exception of SDF-1α (n = 28). The characteristics of the study population were shown in the clinical report (Kulke et al, 2008). At baseline, median SDF-1α and sVEGFR-2 concentrations were significantly higher in pNET compared with carcinoid (1235.7 ± 414.8 pg ml⁻¹, P = 0.003, and 9562 pg ml⁻¹ vs 8722 pg ml⁻¹, P = 0.041, respectively; Table 1). Patients with pNET also showed a trend towards higher VEGF levels. Baseline sVEGFR-3 and IL-8 did not differ between tumour types. No correlation was found between the concentrations of four of the soluble factors and the tumour burden (estimated using RECIST’s sum of longest diameters (SLD)), using a regression model (ρ = 0.0059 for VEGF, ρ = 0.0005 for sVEGFR-2, ρ = 0.0166 for sVEGFR-3, and ρ = 0.0297 for IL-8; all P > 0.05).

Changes in soluble protein biomarkers during treatment and correlation with drug exposure. At C1D28, sunitinib treatment was associated with significant increases from baseline in VEGF, IL-8, and SDF-1α, and decreases in sVEGFR-2 and sVEGFR-3 (Table 1 and Supplementary Figure S2), with no difference between tumour types (Table 1). Very mild to moderate but significant correlations between plasma trough drug levels (Cₘₚₐₚ) by C1D28 for sunitinib and changes in VEGF (ρ = 0.30, P < 0.001), sVEGFR-3 (ρ = 0.23, P < 0.001), and IL-8 (ρ = 0.09, P = 0.014) were found in patients with pNET, but not for sVEGFR-2 (ρ = 0.05, P = 0.067). In patients with carcinoid tumours, only sVEGFR-3
concentrations ($\rho = 0.33$, $P < 0.001$) correlated with drug level. However, no correlation was observed for VEGF ($\rho = 0.06$), sVEGFR-2 ($\rho = 0.02$) or IL-8 ($\rho = 0.10$).

**Relationship between protein biomarkers and outcomes**

**Pancreatic NET.** No significant associations were found between soluble protein levels and CBR or PFS (Table 2). However, above-median (‘high’) baseline sVEGFR-2 levels predicted for longer OS ($P = 0.005$, hazard ratio (HR): 0.22, 95% confidence interval (95% CI): 0.06–0.78).

**Carcinoid tumours.** Only baseline IL-8 levels were lower in patients with CBR ($11.3$ vs $30.8$ pg ml$^{-1}$; $P = 0.005$). High sVEGFR-2 and IL-8 levels correlated with shorter PFS ($P = 0.006$, HR for progression/death: 3.91, 95% CI: 1.38–11.10 and $P = 0.045$, HR: 2.58, 95% CI: 0.98–6.87), respectively, and shorter OS ($P = 0.047$, HR for death: 0.22, 95% CI: 0.06–0.78, respectively) and shorter OS ($P = 0.014$, HR: 5.51, 95% CI: 1.20–25.32, respectively; Table 2 and Figure 1).

**Stromal cell-derived factor-1z.** Owing to the limited number of samples ($n = 28$; $14$ pNET and $14$ carcinoid), the relationships between SDF-1z and outcomes were investigated in all available patients as a group. In this cohort, the two disease groups (Supplementary Table S1) did not differ in terms of PFS ($P = 0.06$) or OS ($P = 0.48$). Progression or death occurred in $22$ patients. Using fitted Cox models for PFS and OS that included SDF-1z concentrations and disease group as covariates, high SDF-1z predicted for an increased risk of progression or death (PFS: $P = 0.005$, HR: $3.59$, 95% CI: $1.47–8.76$ and OS: $P = 0.02$, HR: $2.34$, 95% CI: $1.16–4.72$). Patients achieving CBR had lower SDF-1z concentrations (median 418 (range 210–1760) vs median 1069 (range 229–2219) pg ml$^{-1}$; $P = 0.04$).

**Changes in WBC and monocyte subsets during sunitinib treatment.** All WBC types, except lymphocytes and basophils, showed highly significant changes during the first three cycles of sunitinib, most notably a decrease in monocytes (greater than for any of the other WBC types, with the exception of that for neutrophils on C1D28; Wilcoxon signed-rank test; Figure 2A, and Supplementary Tables S3 and S4). The decrease in monocyte count correlated negatively with the plasma trough drug levels ($C_{\text{min}}$) by C1D28 ($\rho = 0.22$, $P = 0.03$).

Peripheral blood mononuclear cell specimens from $17$ patients were assessed by flow cytometry at baseline, C1D14, C1D28, and C2D1. On sunitinib, CD4+ monocyte subpopulations decreased, in particular those bearing VEGFR-1 or CXCR4 (median change from C1D1 to C1D14, $–50$ cells per μl and $–5$ cells per μl, $P = 0.04$ and $P = 0.03$, respectively; median change from

---

### Table 1. Baseline levels of soluble proteins and ratios of C1D28 to baseline levels during sunitinib treatment

| Biomarker | All patients, median (range) | N | P-value | Carcinoid tumour, median (range) | N | pNET, median (range) | N | P-value* |
|-----------|-----------------------------|---|---------|---------------------------------|---|----------------------|---|---------|
| VEGF Baseline, pg ml$^{-1}$ | 38.6 (8.2–408.5) | 101 | 0.479 | 30.1 (9.2–138.9) | 37 | 43.4 (8.2–408.5) | 64 | 0.069 |
| VEGF C1D28:C1D1 | 3.4 | 100 | <0.0001 | 0.6 | 3.6 | 35 | 3.2 | 65 | 0.599 |
| sVEGFR-2 Baseline, pg ml$^{-1}$ | 9120 (3251–15689) | 104 | 0.0001 | 8722 (3251–12776) | 39 | 9562 (3894–15689) | 65 | 0.041 |
| sVEGFR-2 C1D28:C1D1 | 0.7 | 102 | <0.0001 | 0.8 | 37 | 0.6 | 65 | 0.105 |
| sVEGFR-3 Baseline, pg ml$^{-1}$ | 100800 (30 700–2 569 000) | 104 | 0.0001 | 96 800 (43 500–2 569 000) | 39 | 100 800 (30 700–1 684 000) | 65 | 0.817 |
| sVEGFR-3 C1D28:C1D1 | 0.6 | 98 | <0.0001 | 0.6 | 34 | 0.6 | 65 | 0.429 |
| IL-8 Baseline, pg ml$^{-1}$ | 16.9 (3.3–763.1) | 104 | 0.008 | 15.0 (3.3–763.1) | 39 | 17.6 (6.1–130.3) | 65 | 0.302 |
| IL-8 C1D28:C1D1 | 1.8 | 99 | 0.027 | 1.4 | 36 | 1.8 | 66 | 0.528 |
| SDF-1z Baseline, pg ml$^{-1}$ | 583.4 (209.9–2 218.8) | 28 | 0.027 | 414.8 (209.9–2 218.8) | 14 | 1 235.7 (285.7–2 049.8) | 14 | 0.003 |
| SDF-1z C1D28:C1D1 | 1.2 | 21 | 0.027 | 1.8 | 10 | 1.1 | 11 | 0.053 |

**Table 2. Correlation between plasma markers and outcomes by tumour type**

| Biomarker | Carcinoid tumour | pNET |
|-----------|------------------|------|
| VEGF Baseline, pg ml$^{-1}$ | 30.3 (9–138.9) | 0.479 |
| SDF-1z Baseline, pg ml$^{-1}$ | 96800 (43 500–2 569 000) | 0.006 |
| IL-8 Baseline, pg ml$^{-1}$ | 15.0 (3.3–763.1) | 0.045 |

**Table 2. Correlation between plasma markers and outcomes by tumour type**

| Biomarker | Median (range) | N | P-values | HR (95% CI) | Median (range) | N | P-values | HR (95% CI) |
|-----------|---------------|---|----------|-------------|---------------|---|----------|-------------|
| VEGF Baseline, pg ml$^{-1}$ | 30.3 (9.2–138.9) | 37 | 0.479 | 0.715 (0.280–1.826) | 0.86 | 0.325 (0.085–1.257) | 43.4 (8.2–408.5) | 64 | 0.237 | 1.533 (0.751–3.130) |
| SDF-1z Baseline, pg ml$^{-1}$ | 96800 (43 500–2 569 000) | 39 | 0.006 | 3.227 (0.957–10.88) | 9562 (3894–15689) | 65 | 0.206 | 0.639 (0.317–1.290) |
| IL-8 Baseline, pg ml$^{-1}$ | 15.0 (3.3–763.1) | 39 | 0.045 | 2.58 (0.985–6.780) | 0.014 | 5 507 (1 198–25.32) | 17.6 (6.1–130.3) | 65 | 0.135 | 1.700 (0.839–3.446) |

**Abbreviations:** CNDM = cycle number, day number; IL-8 = interleukin 8; pNET = pancreatic neuroendocrine tumour; SDF-1z = stromal cell-derived factor 1z; sVEGFR-2 = soluble VEGF receptor 2; sVEGFR-3 = soluble VEGF receptor 3; VEGF = vascular endothelial growth factor. P-values $<0.05$ are underlined and shown in bold.

**Abbreviations:** CI = confidence interval; HR = hazard ratio; IL-8 = interleukin 8; OS = overall survival; PFS = progression-free survival; pNET = pancreatic neuroendocrine tumour; sVEGFR-2 = soluble VEGF receptor 2; sVEGFR-3 = soluble VEGF receptor 3; VEGF = vascular endothelial growth factor. P-values $<0.05$ are underlined and shown in bold.
C1D1 to C1D28, –54 cells per µl and –3 cells per µl, \( P = 0.02 \) and \( P = 0.07 \), respectively; Wilcoxon signed rank-sum test; Figure 2B and Supplementary Table S5).

**Changes in CECs.** During the first sunitinib cycle, mature CECs decreased from baseline in the 17 available specimens (median change –3 cells per µl and –4 cells per µl, \( P = 0.037 \) and \( P = 0.045 \) for D14 and D28, respectively). There were no significant changes in circulating endothelial progenitor (CEP) cell levels during cycle 1 (not shown) or in CEC subtypes at day 42 relative to baseline (after 2 weeks off therapy).

**Exploratory correlations between changes in cellular and plasma markers.** Change from baseline to C1D28 in monocyte count showed moderately positive correlations with sVEGFR-3 change in all patients (\( r = 0.32, P = 0.04 \), particularly in those with carcinoid (\( r = 0.37, P = 0.04 \)), and with sVEGFR-2 changes in patients with pNET (\( r = 0.31, P = 0.01 \); Table 3).

Positive correlations were observed between changes in IL-8 and CXCR4-expressing monocytes and CEP (\( r = 0.58, P = 0.03 \) and \( r = 0.71, P = 0.006 \), respectively), suggesting that IL-8 may contribute to mobilization and/or tumour recruitment of these cells. Negative correlations were found between changes in sVEGFR-2 and sVEGFR-3, and mature CEC (\( r = -0.62, P = 0.03 \) and \( r = -0.58, P = 0.04 \), respectively; Table 4), adding to their pharmacodynamic value.

**DISCUSSION**

Molecular classifiers are urgently needed to better assess prognosis and optimize drug selection in NET. This analysis of circulating protein and cellular biomarkers in sunitinib-treated patients with pNET and carcinoid identified differences between tumour types.
importance of IL-8 in the biology of carcinoids however remains modulated by VEGF and possibly serve as a surrogate biomarker resistance in renal cell carcinoma (Huang 2007; Norden-Zfoni et al 2007; Lindauer et al 2007; Norden-Zfoni et al 2007; Lindauer et al 2011). Most of these changes are related to the effects of the drug on host rather than tumour cells (Ebos et al 2007; Lindauer et al 2010).

Sunitinib exerts antitumour and antiangiogenic effects via tyrosine kinase inhibition on signalling cascades that regulate tumour growth, survival, and angiogenesis. Although the biologic targets of sunitinib are known and clinically validated, the cellular and molecular determinants of clinical benefit are still unclear. In our study, high pre-treatment sVEGFR-2 levels were associated with longer OS in patients with pNET, the first such report to the best of our knowledge. Other groups however have shown high levels of sVEGFR-2 to predict for PFS benefit from anti-VEGF treatment in different cancer types, including metastatic NETs (Cameron et al 2013; Grande et al 2013; Miles et al 2013; Cremolini et al 2014). VEGFR-2 plasma levels are thought to be modulated by VEGF and possibly serve as a surrogate biomarker for VEGF-dependent tumour growth (Ebos et al 2008). In patients with carcinoids, low pre-treatment IL-8 levels predicted for CBR, longer PFS, and longer OS, indicating that IL-8 is a candidate marker of prognosis and/or sunitinib treatment benefit in these patients. Indeed, IL-8 has been reported as possibly prognostic in a smaller study that included carcinoid, pNET, and poorly differentiated neuroendocrine carcinomas (Pavel et al 2005), perhaps through its effects favouring angiogenesis (directly on endothelial cells and by attracting myeloid cells to the tumour) and malignant cell proliferation and migration. High IL-8 expression has also been linked to prognosis (Tran et al 2012) and sunitinib resistance in renal cell carcinoma (Huang et al 2010). The relative importance of IL-8 in the biology of carcinoids however remains an open question. Regarding sVEGFR-3, we observed that low baseline levels also predicted for longer PFS and OS in carcinoid tumours. VEGFR-3, which is restricted in expression to the mucosal lymphatics of the intestines (not in blood capillaries; Partanen et al, 2000), may be an important sunitinib target in this tumour type through its role in lymphangiogenesis (Alitalo and Deprimo, 2000). We found low SDF-1α concentrations associated with CBR and longer PFS and OS in a pooled subgroup of patients including both carcinoid and pNET. Consistently, high expression of SDF-1 in pNET cells in tissue was previously linked to variables representing tumour growth and metastasis (Takahashi et al, 2007), while the expression of its receptor CXCR4 has been implicated in the metastatic potential of ileal carcinoid tumours (Arvidsson et al, 2010). Our findings suggest that the SDF-1α/CXCR4 pathway and the relative value of IL-8, SVEGFR-2, and sVEGFR-3 should be further investigated in well-differentiated NET in comparison with other emerging markers of prognosis such as chromogranin A and neuron-specific enolase (Yao et al, 2011; Chou and Chang Gung, 2013).

Among WBC types, sunitinib led to a distinct decrease in monocytes, specifically CD14+ monocyte subpopulations bearing VEGFR-1 and CXCR4, suggesting that these cells may be useful markers of sunitinib activity and response. The rationale for evaluating monocyte subsets was threefold. First, they express molecular targets for sunitinib: we previously showed that the majority of VEGFR-1-expressing WBCs in peripheral blood are CD14+ monocytes (Norden-Zfoni et al, 2007), which can co-express other targets such as PDGFR, KIT, and CD115. Second, myelomonocytic cells under different designations facilitate angiogenesis, tumour progression, and metastasis (Bergers and Hanahan, 2008; Du et al, 2008). Third, they have been implicated in tumour refractoriness to anti-VEGF therapy in animal models (Bergers and Hanahan, 2008). Together, our results suggest that the specific targeting of VEGFR-1 and CXCR4 monocytes may be a novel and important contributor to the effectiveness of sunitinib and perhaps other VEGFR-targeted agents in NET and other cancer types. Compared with CECs, the evaluation of myelomonocytic cell subpopulations in clinical specimens is more robust. CECs are extremely rare (1–2 orders of magnitude less common than VEGFR-1 monocytes in this study) and difficult to reliably quantify. Future studies should be considered in larger, more homogeneous patient sets to better assess correlations with prognosis and/or treatment outcomes.

### Table 4. Correlation between changes from baseline to C1D28 in soluble protein and cellular biomarkers (monocytes and CEC)

| VEGFR-1 + monocytes | VEGF | sVEGFR-2 | sVEGFR-3 | IL-8 | SDF-1α |
|---------------------|------|---------|----------|------|--------|
| Spearman correlation coefficient | -0.2527 | -0.23956 | 0.51648 | -0.07253 | 0.21818 |
| P-value | 0.4048 | 0.4094 | 0.0586 | 0.8054 | 0.5192 |
| Sample size | 13 | 14 | 14 | 14 | 11 |

| CXCR4 + monocytes | VEGF | sVEGFR-2 | sVEGFR-3 | IL-8 | SDF-1α |
|------------------|------|---------|----------|------|--------|
| Spearman correlation coefficient | 0.09341 | -0.35824 | 0.01538 | 0.57802 | 0.31818 |
| P-value | 0.7615 | 0.2085 | 0.9584 | 0.0304 | 0.3403 |
| Sample size | 13 | 14 | 14 | 14 | 11 |

| CEP | VEGF | sVEGFR-2 | sVEGFR-3 | IL-8 | SDF-1α |
|-----|------|---------|----------|------|--------|
| Spearman correlation coefficient | -0.01408 | 0.01657 | 0.35360 | 0.71272 | -0.30277 |
| P-value | 0.9653 | 0.9571 | 0.2359 | 0.0063 | 0.3655 |
| Sample size | 13 | 13 | 13 | 13 | 11 |

| CEC | VEGF | sVEGFR-2 | sVEGFR-3 | IL-8 | SDF-1α |
|-----|------|---------|----------|------|--------|
| Spearman correlation coefficient | 0.49650 | -0.65138 | -0.57692 | 0.09340 | 0.05495 |
| P-value | 0.4096 | 0.0252 | 0.0390 | 0.8585 | 0.655 |
| Sample size | 12 | 13 | 13 | 13 | 11 |

Abbreviations: CEC = circulating endothelial cell; CEP = circulating endothelial progenitor cell; SDF-1α = stromal cell-derived factor 1α; VEGFR-1 = vascular endothelial growth factor receptor. Correlation coefficients with P-values < 0.05 are shown in bold.
As all patients in our study received sunitinib, we cannot determine whether the associations between biologic and clinical endpoints were treatment related. Moreover, we did not use correction for multiple testing, because our goal was to be inclusive and not miss any candidate biomarker in the limited sample set. Our findings regarding IL-8 and sVEGFR-3 in carcinoid tumours, sVEGFR-2 in NETs, and in the limited sample set. Our findings regarding IL-8 cannot determine whether the associations between biologic

**ACKNOWLEDGEMENTS**

We thank Dr James C Yao for valuable insights. This study was sponsored by Pfizer Inc. Editorial assistance was provided by Susanne Gilbert and Emily Seidman at ACUMED (New York, NY, USA) and was funded by Pfizer Inc.

**CONFLICT OF INTEREST**

Employment or leadership position: LT and XH, Pfizer; WC, MindPiece Partners, prior employee of Pfizer; SEDP, prior employee of Pfizer. Consultant or advisory role: MHK, Novartis, Pfizer, Lexicon; CSH, Pfizer (was an employee of Atrium Staffing (New York, NY, USA) and a paid contractor of Pfizer during the development of this manuscript and the analysis and interpretation of the data); JHV, Pfizer. Stock ownership: LT, XH, WC, Pfizer; Charles S. Harmon, Pfizer (family member). Honoraria: JHV, Pfizer. Research funding: AJZ, WC and JHV, Pfizer; MHK, Novartis. Expert testimony: MHK, Pfizer. Other remuneration: None. MK, H-KW, H-JL, NJM, EL, and XW declare no conflicts of interest.

**REFERENCES**

Abdel-Rahman O (2014) Vascular endothelial growth factor (VEGF) pathway and neuroendocrine neoplasms (NENs): prognostic and therapeutic considerations. *Tumour Biol* 35(11): 10615–10625.

Altalal A, Detmar M (2012) Interaction of tumour cells and lymphatic vessels in cancer progression. *Oncogene* 31(42): 4499–4508.

Arvidsson Y, Bergstrom A, Arvidsson L, Kristiansson E, Ahlman H, Nilsson O (2010) Hypoxia stimulates CXCR4 signalling in ileal carcinoids. *Endocr Relat Cancer* 17(2): 303–316.

Auernhammer CJ, Goke B (2011) Therapeutic strategies for advanced neuroendocrine carcinomas of jejunum/ileum and pancreatic origin. *Gut* 60(7): 1009–1021.

Bergers G, Hanahan D (2008) Modes of resistance to anti-angiogenic therapy. *Nat Rev Cancer* 8(8): 592–603.

Bosman FT, World Health Organization. International Agency for Research on Cancer (2010) WHO Classification of Tumours of the Digestive System. 4th edn (International Agency for Research on Cancer: Lyon).

Cameron D, Brown J, Dent R, Jackisch C, Mackey J, Pivot X, St Cyr CL, Suter TM, Toi M, Parmar M, Laeufle R, Im YH, Romieu G, Harvey V, Lipatov O, Pienkowski T, Crottes P, Chan A, Im SA, Hall PS, Bubulevitch-Picaud L, Henschel V, Deurloo RJ, Pallaud C, Bell R (2013) Adjunctive bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. *Lancet Oncol* 14(10): 933–942.

Chou W-C, Chang Gung L (2013) Baseline and dynamic plasma chromogranin A (CgA) level to predict clinical outcome and tumor response in Asian patients with gastroenteropancreatic neuroendocrine tumor (GEP-NET). *J Clin Oncol* 31(suppl): abstr e15151.

Cremolini C, Lopapais F, Bocci G, Falcone A (2014) Biomarkers and response to bevacizumab–letter. *Clin Cancer Res* 20(4): 1056–1057.

Deprimo SE, Bello CL, Smeraglia J, Baum CM, Spinella D, Rini BI, Michaelson MD, Motzer RJ (2007) Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. *J Transl Med* 5: 32.

Du R, Lu KV, Petritsch C, Liu P, Ganns R, Passgue E, Song H, Vandenberg S, Johnson RS, Werb Z, Berghers G (2008) HIF alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. *Cancer Cell* 13(3): 206–220.

Ebos JM, Lee CR, Bogdanovic E, Alam J, Van Slyke P, Francia G, Xu P, Mutsaers AJ, Dumont DJ, Kerbel RS (2008) Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth. *Cancer Res* 68(2): 521–529.

Ebos JM, Lee CR, Christensen JG, Mutsaers AJ, Kerbel RS (2007) Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. *Proc Natl Acad Sci USA* 104(3): 17069–17074.

Fjallskog ML, Lejonkoul MH, Oberg KE, Eriksson BK, Janson ET (2003) Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib. *J Transl Med* 9: 120.

Huang D, Ding Y, Zhou M, Rini BI, Petrits P, Qian CN, Kahnoski R, Futtreal PA, Forje KA, Teh BT (2010) Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. *Cancer Res* 70(3): 1063–1071.

Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, Berglund E, Stuart T, Tye L, Huang X, Li JZ, Baum CM, Fuchs CS (2008) Activity of sunitinib in patients with advanced neuroendocrine tumors. *J Clin Oncol* 26(30): 3430–3441.

Kulke MH, Siu LL, Tepper JE, Fisher G, Jaffe D, Haller DG, Ellis LM, Benedetti JK, Bergland EK, Hobday TJ, Van Cutsem E, Pingank J, Oberg K, Cohen SJ, Posner MC, Yao JC (2011) Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. *J Clin Oncol* 29(7): 934–943.

Lindauer A, Di Gion P, Kanefendt F, Tomalik-Charte D, Kinzig M, Rodamer M,odos F, Sorge F, Fuhr U, Jaehde U (2010) Pharmacokinetic/pharmacodynamic modeling of biomarker response to sunatinib in healthy volunteers. *Clin Pharmacol Ther* 87(5): 601–608.

Mancuso P, Antoniotti P, Quarna J, Balleri A, Rabascio C, Tacchetti C, Bollottini P, Wu HK, Zurita AJ, Saronni L, Cheng JB, Shalinsky DR, Heymach JV, Bertolini F (2009) Validation of a standardized method for enumerating circulating endothelial cells and progenitors: flow cytometry and molecular and ultrastructural analyses. *Clin Cancer Res* 15(1): 267–273.

Miles DW, de Haas SL, Dirxe LY, Romieu G, Chan A, Pivot X, Tomczak P, Provencher L, Cortes J, Delmar PR, Scherer SJ (2013) Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HIR2-negative metastatic breast cancer. *Br J Cancer* 108(5): 1052–1060.

Norden-Zaoni A, Desai J, Manola J, Beaudry P, Force J, Maki R, Folkman J, Bello C, Baum C, DePristo SE, Shalinsky DR, Demetri GD, Heymach JV (2007) Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. *Clin Cancer Res* 13(9): 2643–2650.

Oberg K (2009) Genetics and molecular pathology of neuroendocrine gastrointestinal and pancreatic tumors (gastroenteropancreatic
neuroendocrine tumors). Curr Opin Endocrinol Diabetes Obes 16(1): 72–78.
Panzuto F, Boninsegna L, Fazio N, Campana D, Pia Brizzi M, Capurso G, Scarpa A, De Braud F, Dogliotti L, Tomassetti P, Delle Fave G, Falconi M (2011) Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. J Clin Oncol 29(17): 2372–2377.
Panzuto F, Nasoni S, Falconi M, Corleto VD, Capurso G, Cassetta S, Di Fonzo M, Tornatore V, Milione M, Angeletti S, Cattaruzza MS, Ziparo V, Bordi C, Pedrleroli P, Delle Fave G (2005) Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer 12(4): 1083–1092.
Pape UF, Berndt U, Muller-Nordhorn J, Bohmig M, Roll S, Koch M, Willich SN, Wiedenmann B (2008) Prognostic factors of long-term outcome in gastrointestinal neuroendocrine tumours. Endocr Relat Cancer 15(4): 1083–1097.
Partanen TA, Arola J, Saaristo A, Jussila L, Ora A, Miettinen M, Stacker SA, Achen MG, Alitalo K (2000) VEGF-C and VEGF-D expression in neuroendocrine cells and their receptor, VEGFR-3, in fenestrated blood vessels in human tissues. FASEB J 14(13): 2087–2096.
Pavel ME, Hassler G, Baum U, Hahn EG, Lohmann T, Schuppan D (2005) Circulating levels of angiogenic cytokines can predict tumour progression and prognosis in neuroendocrine carcinomas. Clin Endocrinol (Oxf) 62(4): 434–443.
Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Horsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364(6): 501–513.
Sanmamed MF, Carranza-Rua O, Alfaro C, Onate C, Martin-Algarra S, Perez G, Landazuri SF, Gonzalez A, Gross S, Rodriguez I, Munoz-Calleja C, Rodriguez-Ruiz M, Sangro B, Lopez-Picazo JM, Rizzo M, Mazzolini G, Pasqual JL, Anduexa MP, Perez-Gracia JL, Melero I (2014) Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins. Clin Cancer Res 20(22): 5697–5707.
Takahashi Y, Akishima-Fukasawa Y, Kobayashi N, Sano T, Kosuge T, Nimura Y, Kanai Y, Hiraoka N (2007) Prognostic value of tumor architecture, tumor-associated vascular characteristics, and expression of angiogenic molecules in pancreatic endocrine tumors. Clin Cancer Res 13(1): 187–196.
Tran HT, Liu Y, Zurita AJ, Lin Y, Baker-Neblett KL, Martin AM, Figlin RA, Hutson TE, Sternberg CN, Amado RG, Pandite LN, Heymach JV (2012) Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol 13(8): 827–837.
Yao JC, Pavel M, Phan AT, Kukle MH, Hoosen S, St Peter J, Cherfi A, Oberg KE (2011) Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. J Clin Endocrinol Metab 96(12): 3741–3749.
Zhang L, Smyrk TC, Oliveira AM, Lohse CM, Zhang S, Johnson MR, Lloyd RV (2009) KIT is an independent prognostic marker for pancreatic endocrine tumors: a finding derived from analysis of islet cell differentiation makers. Am J Surg Pathol 33(10): 1562–1569.

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License.

Supplementary Information accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)